BR112017006425A2 - derivado de isoxazol como inibidor de isocitrato desidrogenase 1 mutante - Google Patents
derivado de isoxazol como inibidor de isocitrato desidrogenase 1 mutanteInfo
- Publication number
- BR112017006425A2 BR112017006425A2 BR112017006425A BR112017006425A BR112017006425A2 BR 112017006425 A2 BR112017006425 A2 BR 112017006425A2 BR 112017006425 A BR112017006425 A BR 112017006425A BR 112017006425 A BR112017006425 A BR 112017006425A BR 112017006425 A2 BR112017006425 A2 BR 112017006425A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- isocitrate dehydrogenase
- isoxazole derivative
- mutant isocitrate
- protein
- Prior art date
Links
- 229940123392 Isocitrate dehydrogenase 1 inhibitor Drugs 0.000 title 1
- 150000002545 isoxazoles Chemical class 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
a presente invenção refere-se a um composto da formula geral (i) tendo uma estrutura de isoxazol que tem excelente atividade inibidora contra a proteína idh1 mutante e inibe a produção de 2-hg por esta proteína, enquanto o composto também é capaz de inibir efetivamente o crescimento de vários tumores que expressam a prote-ína. na fórmula, r1, r2, r3, y e z são conforme definidos na reivindi-cação 1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014203475 | 2014-10-01 | ||
JP2014-203475 | 2014-10-01 | ||
JP2015116774 | 2015-06-09 | ||
JP2015-116774 | 2015-06-09 | ||
PCT/JP2015/077916 WO2016052697A1 (ja) | 2014-10-01 | 2015-10-01 | 変異型イソクエン酸デヒドロゲナーゼ1阻害剤としてのイソキサゾール誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112017006425A2 true BR112017006425A2 (pt) | 2017-12-12 |
BR112017006425B1 BR112017006425B1 (pt) | 2023-02-23 |
BR112017006425B8 BR112017006425B8 (pt) | 2023-05-16 |
Family
ID=55630718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017006425A BR112017006425B8 (pt) | 2014-10-01 | 2015-10-01 | Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos |
Country Status (26)
Country | Link |
---|---|
US (1) | US10040791B2 (pt) |
EP (1) | EP3202766B1 (pt) |
JP (1) | JP6087033B2 (pt) |
KR (1) | KR102440429B1 (pt) |
CN (1) | CN106795146B (pt) |
AU (1) | AU2015325279B2 (pt) |
BR (1) | BR112017006425B8 (pt) |
CA (1) | CA2963359C (pt) |
CO (1) | CO2017003969A2 (pt) |
CY (1) | CY1122891T1 (pt) |
DK (1) | DK3202766T3 (pt) |
ES (1) | ES2779305T3 (pt) |
HR (1) | HRP20200395T1 (pt) |
HU (1) | HUE048997T2 (pt) |
IL (1) | IL251305B (pt) |
LT (1) | LT3202766T (pt) |
MX (1) | MX2017003782A (pt) |
PH (1) | PH12017500530B1 (pt) |
PL (1) | PL3202766T3 (pt) |
PT (1) | PT3202766T (pt) |
RS (1) | RS60064B1 (pt) |
RU (1) | RU2692782C2 (pt) |
SG (1) | SG11201702389XA (pt) |
SI (1) | SI3202766T1 (pt) |
WO (1) | WO2016052697A1 (pt) |
ZA (1) | ZA201703013B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6473270B2 (ja) * | 2015-07-27 | 2019-02-20 | イーライ リリー アンド カンパニー | 7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物及び変異体idh1阻害剤としてのそれらの使用 |
ES2814290T3 (es) | 2016-06-06 | 2021-03-26 | Lilly Co Eli | Inhibidores de IDH1 mutante |
WO2018010142A1 (en) | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
CN111278465A (zh) * | 2017-08-01 | 2020-06-12 | 德国癌症研究中心 | mIDH1抑制剂和DNA低甲基化剂(HMA)的组合 |
MX2018002612A (es) * | 2018-01-29 | 2019-07-30 | Fujifilm Corp | Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo. |
EP4114378A1 (en) | 2020-03-05 | 2023-01-11 | Université de Lausanne | Modulators of aralar for treating neurological disorders |
TW202216139A (zh) | 2020-07-21 | 2022-05-01 | 日商第一三共股份有限公司 | 帝盟多與變異型idh1酵素阻礙劑之組合藥 |
CN116368125A (zh) * | 2020-10-30 | 2023-06-30 | 第一三共株式会社 | 3-甲基-4-卤代-吲哚衍生物的制造方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3194811A (en) | 1963-09-05 | 1965-07-13 | Merck & Co Inc | Aroyl-benzindolyl acids |
US5631269A (en) | 1992-10-23 | 1997-05-20 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
GB2284600A (en) * | 1994-01-21 | 1995-06-14 | Shell Int Research | Herbicidal 3-(hetero)aryl-4-acylisoxazole compositions and compounds |
JP4921162B2 (ja) * | 2003-02-11 | 2012-04-25 | ヴァーナリス(ケンブリッジ)リミテッド | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
RU2392273C2 (ru) * | 2004-09-10 | 2010-06-20 | Синджента Лимитед | Замещенные изоксазолы в качестве фунгицидов |
US20130184222A1 (en) | 2010-07-16 | 2013-07-18 | Agios Pharmaceuticals, Inc | Therapeutically active compositions and their methods of use |
WO2012173682A2 (en) | 2011-03-29 | 2012-12-20 | The Broad Institute, Inc. | Compounds and methods for the treatment of isocitrate dehydrognase related diseases |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
BR112014007310A2 (pt) * | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
EP2804850B1 (en) | 2012-01-19 | 2018-08-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
-
2015
- 2015-10-01 KR KR1020177011877A patent/KR102440429B1/ko active IP Right Grant
- 2015-10-01 JP JP2016552161A patent/JP6087033B2/ja active Active
- 2015-10-01 SG SG11201702389XA patent/SG11201702389XA/en unknown
- 2015-10-01 DK DK15845549.3T patent/DK3202766T3/da active
- 2015-10-01 CN CN201580050809.8A patent/CN106795146B/zh active Active
- 2015-10-01 EP EP15845549.3A patent/EP3202766B1/en active Active
- 2015-10-01 ES ES15845549T patent/ES2779305T3/es active Active
- 2015-10-01 LT LTEP15845549.3T patent/LT3202766T/lt unknown
- 2015-10-01 US US15/516,362 patent/US10040791B2/en active Active
- 2015-10-01 RS RS20200290A patent/RS60064B1/sr unknown
- 2015-10-01 PT PT158455493T patent/PT3202766T/pt unknown
- 2015-10-01 MX MX2017003782A patent/MX2017003782A/es unknown
- 2015-10-01 SI SI201531109T patent/SI3202766T1/sl unknown
- 2015-10-01 WO PCT/JP2015/077916 patent/WO2016052697A1/ja active Application Filing
- 2015-10-01 CA CA2963359A patent/CA2963359C/en active Active
- 2015-10-01 HU HUE15845549A patent/HUE048997T2/hu unknown
- 2015-10-01 RU RU2017114005A patent/RU2692782C2/ru active
- 2015-10-01 PL PL15845549T patent/PL3202766T3/pl unknown
- 2015-10-01 AU AU2015325279A patent/AU2015325279B2/en active Active
- 2015-10-01 BR BR112017006425A patent/BR112017006425B8/pt active IP Right Grant
-
2017
- 2017-03-21 IL IL251305A patent/IL251305B/en active IP Right Grant
- 2017-03-22 PH PH12017500530A patent/PH12017500530B1/en unknown
- 2017-04-24 CO CONC2017/0003969A patent/CO2017003969A2/es unknown
- 2017-04-28 ZA ZA2017/03013A patent/ZA201703013B/en unknown
-
2020
- 2020-03-10 HR HRP20200395TT patent/HRP20200395T1/hr unknown
- 2020-03-13 CY CY20201100221T patent/CY1122891T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017006425A2 (pt) | derivado de isoxazol como inibidor de isocitrato desidrogenase 1 mutante | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
EA201990202A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
CR20160229A (es) | Inhibidires de bromodominio | |
DOP2016000248A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
EA201591743A1 (ru) | СТИМУЛЯТОРЫ sGC | |
BR112017004704A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo | |
EA201201648A1 (ru) | Стимуляторы sgc | |
CL2017001650A1 (es) | Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis. | |
BR112016007427A2 (pt) | compostos de pirazol-amida e usos dos mesmos | |
AR088983A1 (es) | Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
BRPI1100666A2 (pt) | Método para produzir um l-aminoácido | |
CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
BR112016029465A2 (pt) | chapa de aço elétrica | |
NI201500115A (es) | Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
CO2019012125A2 (es) | Inhibidores ip6k | |
BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
BR112017007971A2 (pt) | composição para a aquicultura, composição alimentar para aquicultura, banho de imersão para espécies aquáticas e uso de um composto protetor externo para espécies aquáticas | |
MX2014008336A (es) | Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico. | |
BR112018071158A2 (pt) | composições inovadoras | |
CR20170261A (es) | Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2720 DE 23/02/2023, QUANTO AO ITEM (72) NOME DO INVENTOR, DEVIDO ERRO MATERIAL DO PROPRIO. |